Citius Oncology, Current Valuation vs. Number Of Shares Shorted
| CTOR Stock | 0.85 0.13 13.27% |
For Citius Oncology, profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Citius Oncology, to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Citius Oncology, utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Citius Oncology,'s most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Citius Oncology, over time as well as its relative position and ranking within its peers.
Citius |
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Citius Oncology,. If investors know Citius will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Citius Oncology, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Citius Oncology, is measured differently than its book value, which is the value of Citius that is recorded on the company's balance sheet. Investors also form their own opinion of Citius Oncology,'s value that differs from its market value or its book value, called intrinsic value, which is Citius Oncology,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Citius Oncology,'s market value can be influenced by many factors that don't directly affect Citius Oncology,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Citius Oncology,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Citius Oncology, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Citius Oncology,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Citius Oncology, Number Of Shares Shorted vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Citius Oncology,'s current stock value. Our valuation model uses many indicators to compare Citius Oncology, value to that of its competitors to determine the firm's financial worth. Citius Oncology, is the top company in current valuation category among its peers. It also is number one stock in number of shares shorted category among its peers . The ratio of Current Valuation to Number Of Shares Shorted for Citius Oncology, is about 2,949 . Comparative valuation analysis is a catch-all technique that is used if you cannot value Citius Oncology, by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Citius Current Valuation vs. Competition
Citius Oncology, is the top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Health Care industry is currently estimated at about 125.55 Billion. Citius Oncology, adds roughly 116.23 Million in current valuation claiming only tiny portion of equities under Health Care industry.
Citius Number Of Shares Shorted vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Citius Oncology, |
| = | 116.23 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Citius Oncology, |
| = | 39.42 K |
If a large number of investors decide to short sell an equity instrument within a small period of time, their combined action can significantly affect the price of the stock.
Citius Number Of Shares Shorted Comparison
Citius Oncology, is currently under evaluation in number of shares shorted category among its peers.
Citius Oncology, Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Citius Oncology,, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Citius Oncology, will eventually generate negative long term returns. The profitability progress is the general direction of Citius Oncology,'s change in net profit over the period of time. It can combine multiple indicators of Citius Oncology,, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Operating Income | -10.9 M | -11.5 M | |
| Net Loss | -11.4 M | -12 M | |
| Income Before Tax | -10.9 M | -11.5 M | |
| Net Loss | -11.4 M | -12 M |
Citius Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Citius Oncology,. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Citius Oncology, position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Citius Oncology,'s important profitability drivers and their relationship over time.
| Current Valuation vs Shares Outstanding | ||
| Price To Book vs Number Of Shares Shorted | ||
| Current Valuation vs Market Capitalization |
Use Citius Oncology, in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Oncology, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Oncology, will appreciate offsetting losses from the drop in the long position's value.Citius Oncology, Pair Trading
Citius Oncology, Pair Trading Analysis
The ability to find closely correlated positions to Citius Oncology, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Oncology, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Oncology, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Oncology, to buy it.
The correlation of Citius Oncology, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Oncology, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Oncology, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Oncology, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Citius Oncology, position
In addition to having Citius Oncology, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Communication Thematic Idea Now
Communication
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Communication theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Communication Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Citius Stock Analysis
When running Citius Oncology,'s price analysis, check to measure Citius Oncology,'s market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Oncology, is operating at the current time. Most of Citius Oncology,'s value examination focuses on studying past and present price action to predict the probability of Citius Oncology,'s future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Oncology,'s price. Additionally, you may evaluate how the addition of Citius Oncology, to your portfolios can decrease your overall portfolio volatility.